In the Apr 21 session, GERN declined 3.85%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement details standard inducement stock option grants for nine new hires, totaling 855,0...
Analysis
This announcement details standard inducement stock option grants for nine new hires, totaling 855,000 shares at an exercise price of $1.68 and vesting over 4 years. It follows similar grants reported on March 18, 2026 and executive-focused awards on April 14, 2026, underscoring ongoing team build-out after prior restructuring. Investors may watch the scale and frequency of such awards alongside regulatory filings and future earnings to gauge dilution trends and execution on the RYTELO commercialization strategy.
Key Figures
Inducement option shares:855,000 sharesNew hires:9 employeesExercise price:$1.68 per share+4 more
Inducement option shares
855,000 shares
Aggregate stock options to nine new employees
New hires
9 employees
Employees receiving inducement stock options
Exercise price
$1.68 per share
Equal to GERN closing price on April 17, 2026 grant date
"granted by the Compensation Committee ... in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
stock optionsfinancial
"it granted stock options to purchase an aggregate of 855,000 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise pricefinancial
"The stock options have an exercise price of $1.68 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vestingfinancial
"and vest over four years, with 12.5% of the shares underlying the options vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
inducement award planfinancial
"subject to the terms and conditions of Geron’s 2018 Inducement Award Plan"
An inducement award plan is a package of pay, often including stock options or restricted shares, granted to a new employee or executive to attract them to join a company — think of it like a signing bonus paid partly in company stock. Investors care because these awards increase compensation expense and can dilute existing shareholders’ ownership, affecting earnings per share and incentives that shape company strategy.
stock option agreementfinancial
"and the form of stock option agreement under the plan"
A stock option agreement is a formal contract that gives an individual the right to buy or sell a specific number of shares of a company's stock at a set price within a certain period. For investors, it’s an important tool because it can provide opportunities to profit from stock price movements or to protect against potential losses, making it a key element in financial planning and investment strategies.
FOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase an aggregate of 855,000 shares of common stock to nine newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of $1.68 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of employment of such employee and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT: Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What inducement grants did Geron (GERN) announce on April 20, 2026?
Geron granted stock options to purchase 855,000 shares to nine new employees. According to Geron, the options were effective April 17, 2026, and were approved under Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and term of the Geron (GERN) inducement options?
The options have an exercise price of $1.68 per share and a 10-year term. According to Geron, $1.68 equals the closing price on the grant date.
How do the Geron (GERN) inducement stock options vest?
Options vest over four years with 12.5% vesting at the six-month anniversary, then equal monthly installments over 42 months. According to Geron, vesting is subject to continued employment.
Under what plan and rule were Geron's (GERN) inducement awards granted?
The awards were granted under Geron's 2018 Inducement Award Plan and the form stock option agreement. According to Geron, the Compensation Committee approved them under Nasdaq Listing Rule 5635(c)(4).
How many employees received inducement awards from Geron (GERN)?
Nine newly hired employees received inducement stock options totaling 855,000 shares. According to Geron, these grants were material to the employees' acceptance of employment.
Will Geron's (GERN) inducement grants dilute existing shareholders?
The press release details 855,000 option shares but does not quantify dilution impact. According to Geron, the grants follow Nasdaq rule 5635(c)(4) and the 2018 Inducement Award Plan.
